IDiyas

For the Inventor, By the Inventor

Sunnyvale, CA, United States of America

Noa Zerangue

USPTO Granted Patents = 25

 

Average Co-Inventor Count = 2.0

ph-index = 8

Forward Citations = 210(Granted Patents)


Location History:

  • San Carlos, CA (US) (2005 - 2010)
  • Sunnyvale, CA (US) (2008 - 2011)
  • Portola Valley, CA (US) (2008 - 2013)
  • Belmont, CA (US) (2011 - 2016)

Company Filing History:

goldMedal25 out of 142 
 
Xenoport, Inc.
 patents

Years Active: 2005-2016

Loading Chart...
Loading Chart...
25 patents (USPTO):Explore Patents
1. 9452972 - Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof (2016-09-27),
2. 8785443 - Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof (2014-07-22),
3. 8778991 - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use (2014-07-15),
4. 8372881 - Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use (2013-02-12),
5. 8202852 - Creatine phosphate analog prodrugs, compositions and uses thereof (2012-06-19),
6. 8168617 - Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use (2012-05-01),
7. 8148414 - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use (2012-04-03),
8. 7994218 - Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use (2011-08-09),
9. 7919454 - Methods of treating using conjugates transported by a PEPT2 transporter (2011-04-05),
10. 7777070 - Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use (2010-08-17),
11. 7704696 - Screening of compounds for OCTN2 transporter activity (2010-04-27),
12. 7704695 - Screening of compounds for BGT1 transporter activity (2010-04-27),
13. 7700300 - Screening of compounds for GAT2 transporter activity (2010-04-20),
14. 7691584 - Screening of compounds for OCT3 transporter activity (2010-04-06),
15. 7683043 - Creatine phosphate analog prodrugs, compositions and uses thereof (2010-03-23),

Title: The Innovative Journey of Noa Zerangue in Pharmaceutical Advancements

Introduction: Noa Zerangue, based in Sunnyvale, California, has made significant contributions to the field of pharmaceuticals, with an impressive portfolio of 25 patents. His work focuses on innovative methods and compositions that address several critical health conditions, showcasing his dedication to improving medical treatments.

Latest Patents: Among his latest inventions, Zerangue developed methods for using prodrugs of methyl hydrogen fumarate. These patents describe pharmaceutical compositions aimed at treating a variety of diseases, including psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. The innovative methodologies presented in his patents provide new avenues for therapeutic applications of these compounds, showcasing their potential effectiveness in treating complex health issues.

Career Highlights: Throughout his career, Noa Zerangue has demonstrated a strong commitment to innovation in the pharmaceutical industry. His significant number of patents underlines his expertise and continuous pursuit of enhancing treatment options. Working with Xenoport, Inc., he has played a crucial role in pioneering new therapies that harness the power of medicinal chemistry and pharmacology.

Collaborations: Noa has worked alongside notable colleagues such as Mark A Gallop and Peter Virsik, contributing to a collaborative environment that fosters innovation. Their combined expertise and efforts highlight the importance of teamwork in the advancement of groundbreaking pharmaceutical solutions.

Conclusion: Noa Zerangue stands out as a prominent inventor in the field of pharmaceuticals, with his patents paving the way for new treatments that have the potential to improve the lives of many. His ongoing contributions to the industry exemplify the crucial role of inventors in addressing medical challenges through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…